与胃癌相关血清生物标志物研究进展  

Advances in Serum Biomarkers Related to Gastric Cancer

作　　者：任芳芳 张翔[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院检验科,青海 西宁

出　　处：《临床医学进展》2022年第4期3421-3428,共8页Advances in Clinical Medicine

摘　　要：胃癌(gastric carcinoma, GC)是一种普遍但异构疾病排名第五的最常见癌症之一,流行于全球,一直是世界上发病率、死亡率较高的常见肿瘤之一。被认为是最致命的胃肠道癌症。在全球范围内极大影响现代人健康。胃癌是复杂的异质性肿瘤,具有生物学和遗传学多样性。通过传统的手术和化学放射疗法虽然能改善早期胃癌患者的预后,然而一旦疾病传播到远处器官,由于治疗手段的局限性,导致临床结果不佳,因此鉴定新型标志物对于延长患者生存期尤为重要,随着分子标志物鉴定技术的研究进展和生物信息学以及功能基因组学的日益普及和增加,可用的潜在治疗方案也在增加。生物标志物有许多潜在的临床应用,包括筛选、评估风险、确定预后、监测复发和预测治疗。本文综述了近年来胃癌特异性生物标志物研究进展。Gastric cancer (GC) is one of the fifth most common cancers. It is prevalent worldwide and has been one of the common tumors with high incidence of morbidity and mortality in the world. It’s considered the deadliest gastrointestinal cancer. It greatly affects modern health around the world. Gastric cancer is a complex heterogeneous tumor with biological and genetic diversity. Although traditional surgery and chemoradiotherapy can improve the prognosis of patients with early gastric cancer, once the disease spreads to distant organs, due to the limitations of treatment methods, the clinical results are not good. Therefore, identification of novel markers is particularly important to prolong the survival of patients. With the development of molecular marker identification techniques and the increasing popularity and availability of bioinformatics and functional genomics, the potential therapeutic options available are also increasing. Biomarkers have many potential clinical applications, including screening, assessing risk, determining prognosis, monitoring relapse, and predicting treatment. This paper reviews the recent advances in the study of specific biomarkers for gastric cancer.

关 键 词：胃癌 筛选 肿瘤标志物 分子生物 

分 类 号：R735.2[医药卫生—肿瘤]